IFRX

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing first-in-class anti-inflammatory therapeutics targeting the complement system. The company's lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a antibody designed to block the biological activity of complement component C5a. InflaRx is developing vilobelimab for multiple indications including hidradenitis suppurativa, pyoderma gangrenosum, and ANCA-associated vasculitis, as well as other serious inflammatory and autoimmune diseases. The complement system is part of the innate immune system, and excessive activation can lead to inflammatory damage in various diseases. InflaRx is headquartered in Germany with operations in the United States.